INTERVIEW: MEDIAN sees growing value of imaging markers in clinical trials
This article was originally published in Clinica
Executive Summary
Companion diagnostics is a hot topic for both medtech and pharma, but while many firms are looking at blood biomarkers, France’s MEDIAN Technologies has a different approach. The firm is focused on imaging to monitor drug response in cancer in both clinical trials and clinical practice.